Prolongation of rat skin and cardiac allograft survival by low molecular weight heparin

Journal of Surgical Research

Volumn 85, Issue 1, 1999, Pages 83-87

  Shapira, Oz M ^a,b   Rene, Hana ^b   Lider, Ofer ^b   Pfeffermann, Rheuven A ^b   Shemin, Richard J ^a   Cohen, Irun R ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cardiac transplantation; Graft survival; Low molecular weight heparin; Rat; Tumor necrosis factor

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032798199     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1999.5667     Document Type: Article

References (28)

1. Wood R. M., Bick M. W. The effect of heparin on ocular tuberculin reaction. Arch. Ophthal. 61:1959;709.
2. Nelson D. S. The effects of anticoagulants and other drugs on cellular and cutaneous reactions to antigen in guinea pigs with delayed type hypersensitivity. Immunology. 9:1965;219.
3. Halpern B., Milliez P., Largue G., Fray A., Morard J. C. Protective action of heparin in experimental immune nephritis. Nature. 205:1965;257.
4. Taylor H. E., Culling C. F. A. Cytopathic effect of sensitized spleen cells on fibroblasts. Lab. Invest. 15:1966;1960.
5. Currie G. A. Effect of heparin on mixed lymphocyte culture. Nature. 215:1967;164.
6. Chelmicka-Szorc E., Arnason B. G. Partial suppression of experimental allergic encephalomyelitis with heparin. Arch. Neurol. 27:1972;153.
7. Sy M. S., Schneeberger E., McCluskey R., Greene M. I., Rosenberg R. D., Benacerraf B. Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell. Immunol. 82:1983;23.
8. Frieri M., Metclafe D. D. Analysis of the effect of mast cell granules on lymphocyte blastogenesis in the absence and presence of mitogens: Identification of heparin as a granule-associated suppressor factor. J. Immunol. 131:1983;1942.
9. Yamamoto H., Fuyama S., Arai S., Sendo F. Inhibition of mouse natural killer cell cytotoxicity by heparin. Cell. Immunol. 96:1985;409.
10. Lagodzinski Z., Gorski A., Wasik M. Immunosuppressive action of low-dose heparin. Effect on skin allograft survival. Transplantation. 50:1990;714.
11. Gorski A., Gradowska L. L., Nowaczyk, Wasik M., Lagodzinski Z. New strategies of heparin treatment used to prolong allograft survival. Transplant. Proc. 23:1991;2251.
12. Gorski A., Wasik M., Nowaczyk M., Korczak-Kowalska G. Immunomodulating activity of heparin. FASEB J. 5:1991;2287.
13. Lider O., Baharav E., Mekori Y. A., Miller T., Naparstek Y., Vlodavsky I., Cohen I. R. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J. Clin. Invest. 83:1989;752.
14. Lider O., Mekory Y. A., Miller T., Bar-Tana R., Vlodavsky I., Baharav E., Cohen I. R., Naparstek Y. Inhibition of T lymphocyte heparanase by heparin prevents cell migration and cell-mediated immunity. Eur. J. Immunol. 20:1990;493.
15. Lider O., Cahalon L., Gilat D., Hershkovitz R., Siegel D., Margalit R., Shoseyov O., Cohen I. R. A disaccharide that inhibits tumor necrosis factor α is formed from the extracellular matrix by the enzyme heparanase. Proc. Natl. Acad. Sci. USA. 92:1995;5037.
16. Cahalon L., Lider O., Schor H., Avron H., Gilat D., Hershkovitz R., Margalit R., Eshel A., Shoseyov O., Cohen I. R. Heparin disaccharides inhibit tumor necrosis factor-α production by macrophages and arrest immune inflammation in rodents. Int. Immunol. 9:1997;1517.
17. Baharav E., Lider O., Margalit M., Cohen I. R. A modified technique for experimental skin grafting. J. Immunol. Methods. 90:1986;1413.
18. Ono K., Lindsey E. S. Improved technique of heart transplantation in rats. J. Thorac. Cardiovasc. Surg. 45:1969;225.
19. Kirby J. A., Reader J. A., Greta J. P., Parfett G. J., Pepper J. R. Rat heterotopic heart transplantation: Quantification and analysis of cell mediated cytotoxicity. Clin. Exp. Immunol. 71:1988;113.
20. 1A) disparity. Transplantation. 45:1988;943.
21. Naparstek Y., Cohen I. R., Fuks Z., Vlodavsky I. Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature. 310:1984;241.
22. Savion N., Vlodavsky I., Fuks Z. Interaction of T lymphocyte and macrophages with cultured vascular endothelial cells: Attachment, invasion and subsequent degradation of the subendothelial extracellular matrix. J. Cell. Physiol. 118:1984;169.
23. Matzner Y., Bar-Ner M., Yahalom J., Ishai-Michaeli R., Fuks Z., Vlodavsky I. Degradation of heparan sulphate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. J. Clin. Invest. 76:1985;1306.
24. Friedman R., Lider O., Naparstek Y., Fuks Z., Vlodavsky I., Cohen I. R. Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J. Cell. Physiol. 130:1987;85.
25. Fareed J., Kumar A., Walenga J. M., Emanuele R. M., Williamson K., Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fragments. Nouv. Rev. Fr. Hematol. 26:1984;267.
26. Shi C., Lee W. S., He Q., Zhang D., Fletcher D. L. Jr., Newell J. B., Haber E. Immunologic basis of transplant-associated arteriosclerosis. Proc. Natl. Acad. Sci. USA. 93:1996;4051.
27. Clausel N., Molossi S., Sett S., Rabinovitch M. In vivo blockade of tumor necrosis factor-α in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation. 89:1994;2768.
28. Aziz S., Tada Y., Gordon D., McDonald T. O., Fareed J., Verrier E. D. A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine. J. Heart Lung Transplant. 12:1993;634.